Industry Symposium

  • Sponsored by Vera Therapeutics - Emerging Therapies for IgA Nephropathy: Targeting BAFF and APRIL with Atacicept
Time (UTC+8) Topic Speaker Moderator Room
12:15 - 12:30 Overview of the Unmet Need in IgA Nephropathy and Disease Markers Muh Geot Wong
Muh Geot Wong
Room 2 ( 701B )
12:30 - 12:45 Emerging Therapies Targets in IgAN and the Role of Cytokines BAFF and APRIL Sydney Tang
Muh Geot Wong
Room 2 ( 701B )
12:45 - 13:00 Targeting BAFF and APRIL with Atacicept Jonathan Barratt
Muh Geot Wong
Room 2 ( 701B )
13:00 - 13:15 Q & A Muh Geot Wong
Room 2 ( 701B )
  • Sponsored by Novartis
Time (UTC+8) Topic Speaker Moderator Room
12:15 - 12:25 Opening Shang-Jyh Hwang
Room 3 ( 701C )
12:25 - 12:40 Australia's Perspective Germaine Wong
Shang-Jyh Hwang
Room 3 ( 701C )
12:40 - 12:55 Taiwan's Perspective Yi-Wen Chiu
Shang-Jyh Hwang
Room 3 ( 701C )
12:55 - 13:10 Panel Discussion Shang-Jyh Hwang
Room 3 ( 701C )
13:10 - 13:15 Closing Shang-Jyh Hwang
Room 3 ( 701C )
  • Sponsored by DKSH - CKD-MBD in Focus: How Early SHPT Treatment Can Change Long-Term Outcomes
Time (UTC+8) Topic Speaker Moderator Room
12:15 - 12:20 Opening Remark Kuo-Cheng Lu
Room 4 ( 701EF )
12:20 - 12:45 The Importance of Early Calcimimetic Use in SHPT: A Personalized Treatment Perspective Chia-Chao Wu
Kuo-Cheng Lu
Room 4 ( 701EF )
12:45 - 13:10 Early Engagement in SHPT: Clinical Rationale and Japanese Insights Hirotaka Komaba
Kuo-Cheng Lu
Room 4 ( 701EF )
13:10 - 13:15 Q & A Kuo-Cheng Lu
Room 4 ( 701EF )
  • Sponsored by Tai Tien Pharmaceuticals CO., LTD.
Time (UTC+8) Topic Speaker Moderator Room
12:15 - 13:15 Treatment of Renal Anemia during Dialysis Nangaku Masaomi
Der-Cherng Tarng
Room 5 ( 701G )
  • Sponsored by AstraZeneca Taiwan Limited
Time (UTC+8) Topic Speaker Moderator Room
12:30 - 13:30 Emerging Treatments and Barriers for CKD Managements - Road to A Better Kidney Health Hiddo Lambers Heerspink
Mai-Szu Wu
Room 1 ( 701A )
  • Sponsored by Hua Chiang Medical
Time (UTC+8) Topic Speaker Moderator Room
12:30 - 13:10 Expanded HD vs HDF Treatment -Evolution of The Latest Technologies and Future Prospects Akihiro C. Yamashita
Kuo-Cheng Lu
Room 2 ( 701B )
13:10 - 13:25 A Randomized Crossover Trial of Super High-Flux Elisio HX Dialyzer Versus High-Flux Dialyzers on Biomarkers and Quality of Life Outcomes in Maintenance Hemodialysis Patients Ko-Lin Kuo
Kuo-Cheng Lu
Room 2 ( 701B )
13:25 - 13:30 Q & A Kuo-Cheng Lu
Room 2 ( 701B )
  • Sponsored by Novartis
Time (UTC+8) Topic Speaker Moderator Room
12:30 - 12:35 Opening Kuan-Yu Hung
Room 3 ( 701C )
12:35 - 13:15 Unlocking the Future of IgA Nephropathy: Innovative Development for Better Patient Outcomes Chee-Kay Cheung
Kuan-Yu Hung
Room 3 ( 701C )
13:15 - 13:25 Panel Discussion Kuan-Yu Hung
Room 3 ( 701C )
13:25 - 13:30 Closing Kuan-Yu Hung
Room 3 ( 701C )
  • Sponsored by Otsuka
Time (UTC+8) Topic Speaker Moderator Room
12:30 - 13:30 Exploring the Role of B Cells in IgA Nephropathy: Pathogenesis to Progression Muh Geot Wong
Wen-Chih Chiang
Room 4 ( 701EF )
  • Sponsored by Bayer - The Finerenone Era: Enhancing CONFIDENCE and Transforming Management in CKD and T2D
Time (UTC+8) Topic Speaker Moderator Room
12:30 - 12:45 Opening & Session 1 - Finerenone's Role in Preventing Cardiorenal Risk in Patients with CKD and T2D Ming-Ju Wu
Masaomi Nangaku
Ming-Ju Wu
Room 5 ( 701G )
12:45 - 13:00 Session 2 - Unleashing Potential: Overcoming Barriers to Finerenone Adoption in Clinical Practice Tushar Dighe
Masaomi Nangaku
Ming-Ju Wu
Room 5 ( 701G )
13:00 - 13:15 Session 3 - One plus One just more than Two – From Evidence to CONFIDENCE: Empowering Asian Patients through decoding CONFIDENCE Tria Johannes Mann
Masaomi Nangaku
Ming-Ju Wu
Room 5 ( 701G )
13:15 - 13:25 Panel Discussion Masaomi Nangaku
Ming-Ju Wu
Room 5 ( 701G )
13:25 - 13:30 Closing Masaomi Nangaku
Ming-Ju Wu
Room 5 ( 701G )
  • Sponsored by Vantive - HDx Spotlight-- Redefine HD: Bridging the Gap Between Innovation and Daily Practice
Time (UTC+8) Topic Speaker Moderator Room
12:30 - 12:35 Opening Tai-Shuan Lai
Room 6 ( 702 )
12:35 - 13:15 Protecting What Remains: New HDx RCT Insights on Preserving Residual Kidney Function & Improving Outcomes Jang-Hee Cho
Tai-Shuan Lai
Room 6 ( 702 )
13:15 - 13:25 Panel Discussion Tai-Shuan Lai
Room 6 ( 702 )
13:25 - 13:30 Closing Remarks Tai-Shuan Lai
Room 6 ( 702 )
  • Sponsored by Novo Nordisk
Time (UTC+8) Topic Speaker Moderator Room
12:30 - 13:30 Moving from Evidence to Practice of Breakthrough Therapy for Diabetic Kidney Disease Wei-Hung Lin
Wei-Cheng Tseng
Room 7 ( 703 )
  • Sponsored by Vantive - Enhancing Home Dialysis Through Digital Connectivity
Time (UTC+8) Topic Speaker Moderator Room
12:30 - 12:35 Opening Chih-Yu Yang
Room 1 ( 701A )
12:35 - 12:55 Optimizing Outcomes in Home Based PD with Remote Patient Management Chia-Chun Lee
Chih-Yu Yang
Room 1 ( 701A )
12:55 - 13:15 Expanding the Reach of Remote Patient Management: Empowering PD Patients Gangjee Ko
Chih-Yu Yang
Room 1 ( 701A )
13:15 - 13:25 Q & A Chih-Yu Yang
Room 1 ( 701A )
13:25 - 13:30 Closing Chih-Yu Yang
Room 1 ( 701A )
  • Sponsored by Everest Medicines
Time (UTC+8) Topic Speaker Moderator Room
12:30 - 13:30 Why Target the Gut to Treat the Kidneys? A New Treatment Paradigm for IgA Nephropathy Jonathan Barratt
Min-Yu Chang
Yen-Ling Chiu
Room 2 ( 701B )
  • Sponsored by Boehringer Ingelheim
Time (UTC+8) Topic Speaker Moderator Room
12:30 - 13:30 Pushing the Boundaries: Long-Term Renal Preservation with Empagliflozin Across the eGFR Spectrum Bobby Chacko
Mai-Szu Wu
Room 3 ( 701C )
  • Sponsored by FME - Person-Centered Approach to Dialysis Care in the Sustainability Era
Time (UTC+8) Topic Speaker Moderator Room
12:30 - 13:00 Where Do Person-Centered Home Therapies Fit Into the Kidney Life Plan? David Law
Chiu-Ching Huang
Room 4 ( 701EF )
13:00 - 13:30 HDF for Better Outcomes and Sustainability: From Global Evidence to Real-World Practice in Korea Ju-Young Moon
Chiu-Ching Huang
Room 4 ( 701EF )
  • Sponsored by Fresenius Kabi Taiwan Ltd. - How Can Keto-analogues Help in The New Era of CKD Therapy
Time (UTC+8) Topic Speaker Moderator Room
12:30 - 12:35 Opening Chih-Wei Yang
Room 5 ( 701G )
12:35 - 13:15 How Can Keto-analogues Help in the New Era of CKD Therapy Kamyar Kalantar-Zadeh
Chih-Wei Yang
Room 5 ( 701G )
13:15 - 13:30 Q & A Chih-Wei Yang
Room 5 ( 701G )
  • Sponsored by Novartis - Entresto in Nephrology: Expanding the Therapeutic Horizon
Time (UTC+8) Topic Speaker Moderator Room
12:30 - 12:35 Opening Tai-Shuan Lai
Room 6 ( 702 )
12:35 - 13:15 ARNI Beyond the Heart: Unveiling Renal Protection Across the CKD Spectrum Hsuan-Jen Lin
Tai-Shuan Lai
Room 6 ( 702 )
13:15 - 13:25 Panel Discussion Tai-Shuan Lai
Room 6 ( 702 )
13:25 - 13:30 Closing Tai-Shuan Lai
Room 6 ( 702 )
  • Sponsored by GSK
Time (UTC+8) Topic Speaker Moderator Room
12:30 - 13:30 Bridging Risk and Prevention: Shingles Management Insights for Nephrologists I-Wen Wu
Yi-Wen Chiu
Room 7 ( 703 )
  • Sponsored by Bayer - Unlocking the Future of CKD Treatment: Insights from the CONFIDENCE Study and Beyond
Time (UTC+8) Topic Speaker Moderator Room
12/5
12:15 - 12:18
Welcome and Introductions Chih-Ching Lin
Chih-Ching Lin
Exhibitor Spotlight
12/5
12:18 - 12:33
Navigating the Future of CKD Management: Unlocking Mechanisms and Potential of Finerenone - Mechanism of Action, Clinical Benefits with Insights from the CONFIDENCE Study, and Practical Considerations in Combination Treatments for Patients with CKD and T2D Johannes Mann
Chih-Ching Lin
Exhibitor Spotlight
12/5
12:33 - 12:38
Navigating the Future of CKD Management: Unlocking Mechanisms and Potential of Finerenone - Integrating Cardiometabolic and Renal Protection: Treatment Strategies for A 55-year-old Woman with T2D and Early CKD Chih-Ching Lin
Chih-Ching Lin
Exhibitor Spotlight
12/5
12:38 - 12:53
Navigating the Future of CKD Management: Unlocking Mechanisms and Potential of Finerenone - Panel Discussion and Q & A Chih-Ching Lin
Exhibitor Spotlight
12/5
12:53 - 13:03
Tailoring Treatment: Real-world Insights and Practical Applications of Finerenone in Patients with CKD and T2D - Efficacy and Safety of Simultaneous Finerenone and SGLT-2 Inhibitor Initiation: Insights from the CONFIDENCE Asian Subanalysis Eun Hui Bae
Chih-Ching Lin
Exhibitor Spotlight
12/5
13:03 - 13:08
Tailoring Treatment: Real-world Insights and Practical Applications of Finerenone in Patients with CKD and T2D - Clinical Considerations in the Management of CKD and T2D Johannes Mann
Chih-Ching Lin
Exhibitor Spotlight
12/5
13:08 - 13:13
Tailoring Treatment: Real-world Insights and Practical Applications of Finerenone in Patients with CKD and T2D - Panel Discussion and Q & A Chih-Ching Lin
Exhibitor Spotlight
12/5
13:13 - 13:15
Closing Remarks Chih-Ching Lin
Exhibitor Spotlight
  • Sponsored by Boehringer Ingelheim - When the Heart and Kidneys Collide: A Clinical Crosstalk
Time (UTC+8) Topic Speaker Moderator Room
12/6
12:35 - 12:55
CV Case: Initiation of Empagliflozin in Acute MI Patients with Advanced CKD Yi-Hsin Chan
Yi-Wen Chiu
Exhibitor Spotlight
12/6
12:55 - 13:15
Renal Case: Initiation of Empagliflozin in Advanced CKD Patients Szu-Chun Hung
Yi-Wen Chiu
Exhibitor Spotlight
12/6
13:15 - 13:30
Cardio-Renal Care Dialogues: (Q&A Panel & Closing) Yi-Hsin Chan
Szu-Chun Hung
Yi-Wen Chiu
Exhibitor Spotlight
  • Sponsored by Novo Nordisk
Time (UTC+8) Topic Speaker Moderator Room
12/7
10:40 - 11:40
Knowing More About the New Pillar of CKM Treatment Chih-Chao Yang
Shuei-Liong Lin
Exhibitor Spotlight